Faruqi and Faruqui, LLP Logo
Share this page

KemPharm, Inc. (KMPH)

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In KemPharm, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in KemPharm, Inc. (“KemPharm” or the “Company”) (NASDAQ:KMPH) of the federal securities class action lawsuit filed against the Company and certain officers and directors and underwriters of the Company’s April 16, 2015 Initial Public Offering (the “IPO”) to seek the role of lead plaintiff.

The lawsuit has been filed in the Iowa District Court for Johnson County on behalf of all those who acquired KemPharm shares pursuant or traceable to the Company’s IPO.  The case, Christians v. KemPharm, Inc., et al., No. CVCV078476, was filed on November 4, 2016.  It was removed to the Southern District of Iowa on January 12, 2017, where it was docketed at No. 3:17-cv-00002-RP-HCA, and has been assigned to Senior District Judge Robert W. Pratt.

The lawsuit focuses on whether the defendants violated federal securities laws by making false and/or misleading statements and/or failing to disclose in its Registration Statement filed in connection with the IPO that: (1) KemPharm constructed a deficient study in connection with its most advanced drug candidate’s, Apadaz, abuse-deterrent properties; and (2) as a result, Apadaz would not be labeled as an “abuse-deterrent” product by the Federal Drug Administration (the “FDA”).

Specifically, after the market closed on May 5, 2016, the Company announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted against inclusion of abuse deterrent labeling for Apadaz.

On this news, KemPharm’s share price fell from $15.67 per share on May 5, 2016 to a closing price of $6.91 on May 6, 2016 —a $8.76 or a 55.9% drop.

Take Action

If you invested in KemPharm stock and would like to discuss your legal rights, you can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding KemPharm’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    KemPharm, Inc. (KMPH)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 01/20/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.